Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Clinical & Experimental Metastasis
Published in: Clinical & Experimental Metastasis 8/2010

01-12-2010 | Research Paper

Co-expression of CD147/EMMPRIN with monocarboxylate transporters and multiple drug resistance proteins is associated with epithelial ovarian cancer progression

Authors: Hongmin Chen, Li Wang, Julia Beretov, Jingli Hao, Weiwei Xiao, Yong Li

Published in: Clinical & Experimental Metastasis | Issue 8/2010

Login to get access

Abstract

Cancer metastasis and anti-cancer drug resistance are the major reason for the failure of clinical cancer treatment. We evaluated CD147, monocarboxylate transporters (MCT1 and MCT4), and multidrug resistance (MDR) markers (MDR1 and MRP2) in 4 epithelial ovarian cancer (EOC) cell lines and primary tumors (n = 120) along with the matched metastatic lesions (n = 40) with immunofluorescence labeling. We correlated CD147 with MCT1, MCT4, MDR1 and MRP2 markers in primary and metastatic cells in cell lines and tissues using confocal microscopy. We also investigated the relationship of expression of CD147, MCT1 and MCT4 with various progression parameters. Our results indicate that the co-expression of CD147 with MCTs or MDR markers was found in primary and metastatic EOC cells and stromal cells; the over-expression of CD147, MCT1 and MCT4 was found in most primary and the matched metastatic lesions of EOC, and was significantly associated with tumor stage, grade, residual disease status and presence of ascites (P < 0.05) but not with histology type (P > 0.05). These results suggest that over-expression of CD147, MCT1 and MCT4 is correlated with EOC progression, and co-expression of CD147 and MCT1/MCT4 is related to drug resistance during EOC metastasis and could be useful therapeutic targets to prevent the development of incurable, recurrent and drug resistance EOC.
Literature
1.
Baird RD, Kaye SB (2003) Drug resistance reversal—are we getting closer? Eur J Cancer 39:2450–2561CrossRefPubMed
2.
Yan L, Zucker S, Toole BP (2005) Roles of the multifunctional glycoprotein, emmprin (basigin; CD147), in tumour progression. Thromb Haemost 93:199–204PubMed
3.
Gallagher SM, Castorino JJ, Wang D, Philp NJ (2007) Monocarboxylate transporter 4 regulates maturation and trafficking of CD147 to the plasma membrane in the metastatic breast cancer cell line MDA-MB-231. Cancer Res 67:4182–4189CrossRefPubMed
4.
Slomiany MG, Grass GD, Robertson AD, Yang XY, Maria BL, Beeson C, Toole BP (2009) Hyaluronan, CD44, and emmprin regulate lactate efflux and membrane localization of monocarboxylate transporters in human breast carcinoma cells. Cancer Res 69:1293–1301CrossRefPubMed
5.
Martinez-Zaguilan R, Seftor EA, Seftor RE, Chu YW, Gillies RJ, Hendrix MJ (1996) Acidic pH enhances the invasive behavior of human melanoma cells. Clin Exp Metastasis 14:176–186CrossRefPubMed
6.
Tredan O, Galmarini CM, Patel K, Tannock IF (2007) Drug resistance and the solid tumor microenvironment. J Natl Cancer Inst 99:1441–1454CrossRefPubMed
7.
Fang J, Quinones QJ, Holman TL, Morowitz MJ, Wang Q, Zhao H, Sivo F, Maris JM, Wahl ML (2006) The H+-linked monocarboxylate transporter (MCT1/SLC16A1): a potential therapeutic target for high-risk neuroblastoma. Mol Pharmacol 70:2108–2115CrossRefPubMed
8.
Froberg MK, Gerhart DZ, Enerson BE, Manivel C, Guzman-Paz M, Seacotte N, Drewes LR (2001) Expression of monocarboxylate transporter MCT1 in normal and neoplastic human CNS tissues. Neuroreport 12:761–765CrossRefPubMed
9.
Koukourakis MI, Giatromanolaki A, Harris AL, Sivridis E (2006) Comparison of metabolic pathways between cancer cells and stromal cells in colorectal carcinomas: a metabolic survival role for tumor-associated stroma. Cancer Res 66:627–632CrossRef
10.
Kirk P, Wilson MC, Heddle C, Brown MH, Barclay AN, Halestrap AP (2000) CD147 is tightly associated with lactate transporters MCT1 and MCT4 and facilitates their cell surface expression. EMBO J 19:3896–3904CrossRefPubMed
11.
Germann UA (1996) P-glycoprotein—a mediator of multidrug resistance in tumour cells. Eur J Cancer 32A:927–944CrossRefPubMed
12.
13.
Kool M, de Haas M, Scheffer GL, Scheper RJ, van Eijk MJ, Juijn JA, Baas F, Borst P (1997) Analysis of expression of cMOAT (MRP2), MRP3, MRP4, and MRP5, homologues of the multidrug resistance associated protein gene (MRP1), in human cancer cell lines. Cancer Res 57:3537–3547PubMed
14.
Surowiak P, Materna V, Kaplenko I, Spaczynski M, Dolinska-Krajewska B, Gebarowska E, Dietel M, Zabel M, Lage H (2006) ABCC2 (MRP2, cMOAT) can be localized in the nuclear membrane of ovarian carcinomas and correlates with resistance to cisplatin and clinical outcome. Clin Cancer Res 12:7149–7158CrossRefPubMed
15.
Yang H, Zou W, Li Y, Chen B, Xin X (2007) Bridge linkage role played by CD98hc of anti-tumor drug resistance and cancer metastasis on cisplatin-resistant ovarian cancer cells. Cancer Biol Ther 6:942–947CrossRefPubMed
16.
Su J, Chen X, Kanekura T (2009) A CD147-targeting siRNA inhibits the proliferation, invasiveness, and VEGF production of human malignant melanoma cells by down-regulating glycolysis. Cancer Lett 273:140–147CrossRefPubMed
17.
Schneiderhan W, Scheler M, Holzmann KH, Marx M, Gschwend JE, Bucholz M, Gress TM, Seufferlein T, Adler G, Oswald F (2009) CD147 silencing inhibits lactate transport and reduces malignant potential of pancreatic cancer cells in in vivo and in vitro models. Gut 58:1391–1398CrossRefPubMed
18.
Creasman WJ (1998) Announcement, FIGO stages: 1988 revisions. Gynecol Oncol 5:125–127
19.
Deora AA, Philp N, Hu J, Bok D, Rodriguez-Boulan E (2005) Mechanisms regulating tissue-specific polarity of monocarboxylate transporters and their chaperone CD147 in kidney and retinal epithelia. Proc Natl Acad Sci USA 102:16245–16250CrossRefPubMed
20.
Misra S, Ghatak S, Toole BP (2005) Regulation of MDR1 expression and drug resistance by a positive feedback loop involving hyaluronan, phosphoinositide 3-kinase, and ErbB2. J Biol Chem 280:20310–20315CrossRefPubMed
21.
Zou W, Yang H, Hou X, Zhang W, Chen B, Xin X (2007) Inhibition of CD147 gene expression via RNA interference reduces tumor cell invasion, tumorigenicity and increases chemosensitivity to paclitaxel in HO-8910pm cells. Cancer Lett 248:211–218CrossRefPubMed
22.
Kuang YH, Chen X, Su J, Wu LS, Li J, Chang J, Qiu Y, Chen ZS, Kanekura T (2008) Proteome analysis of multidrug resistance of human oral squamous carcinoma cells using CD147 silencing. J Proteome Res 7:4784–4791CrossRefPubMed
23.
Jia L, Wei W, Cao J, Xu H, Miao X, Zhang J (2009) Silencing CD147 inhibits tumor progression and increases chemosensitivity in murine lymphoid neoplasm P388D1 cells. Ann Hematol 88:753–760CrossRefPubMed
24.
Davidson B, Goldberg I, Berner A, Kristensen GB, Reich R (2003) EMMPRIN (extracellular matrix metalloproteinase inducer) is a novel marker of poor outcome in serous ovarian carcinoma. Clin Exp Metastasis 20:161–169CrossRefPubMed
25.
Millimaggi D, Mari M, D’Ascenzo S, Carosa E, Jannini EA, Zucker S, Carta G, Pavan A, Dolo V (2007) Tumor vesicle-associated CD147 modulates the angiogenic capability of endothelial cells. Neoplasia 9:349–357CrossRefPubMed
26.
Jin JS, Yao CW, Loh SH, Cheng MF, Hsieh DS, Bai CY (2006) Increasing expression of extracellular matrix metalloprotease inducer in ovary tumors: tissue microarray analysis of immunostaining score with clinicopathological parameters. Int J Gynecol Pathol 25:140–146CrossRefPubMed
27.
Sillanpaa S, Anttila M, Suhonen K, Hamalainen K, Turpeenniemi-Hujanen T, Puistola U, Tammi M, Sironen R, Saarikoski S, Kosma VM (2007) Prognostic significance of extracellular matrix metalloproteinase inducer and matrix metalloproteinase 2 in epithelial ovarian cancer. Tumour Biol 28:280–289CrossRefPubMed
28.
Gatenby RA, Gillies RJ (2004) Why do cancers have high aerobic glycolysis? Nat Rev Cancer 4:891–899CrossRefPubMed
29.
Izumi H, Torigoe T, Ishiguchi H, Uramoto H, Yoshida Y, Tanabe M, Ise T, Murakami T, Yoshida T, Nomoto M, Kohno K (2003) Cellular pH regulators: potentially promising molecular targets for cancer chemotherapy. Cancer Treat Rev 29:541–549CrossRefPubMed
30.
Pinheiro C, Longatto-Filho A, Scapulatempo C, Ferreira L, Martins S, Pellerin L, Rodrigues M, Alves VA, Schmitt F, Baltazar F (2008) Increased expression of monocarboxylate transporters 1, 2 and 4 in colorectal carcinomas. Virchows Arch 452:139–146CrossRefPubMed
31.
Pinheiro C, Longatto-Filho A, Ferreira L, Pereira SM, Etlinger D, Moreira MA, Jube LF, Queiroz GS, Schmitt F, Baltazar F (2008) Increasing expression of monocarboxylate transporters 1 and 4 along progression to invasive cervical carcinoma. Int J Gynecol Pathol 27:568–574CrossRefPubMed
32.
Koukourakis MI, Giatromanolaki A, Bougioukas G, Sivridis E (2007) Lung cancer: a comparative study of metabolism related protein expression in cancer cells and tumor associated stroma. Cancer Biol Ther 6:1476–1479CrossRefPubMed
33.
Pinheiro C, Longatto-Filho A, Simoes K, Jacob CE, Bresciani CJ, Zilberstein B, Cecconello I, Alves VA, Schmitt F, Baltazar F (2009) The prognostic value of CD147/EMMPRIN is associated with monocarboxylate transporter 1 co-expression in gastric cancer. Euro J Cancer 45:2418–2424CrossRef
34.
Xing H, Wang S, Weng D, Chen G, Yang X, Zhou J, Xu G, Lu Y, Ma D (2007) Knock-down of P-glycoprotein reverses taxol resistance in ovarian cancer multicellular spheroids. Oncol Reports 17:117–122
35.
Penson RT, Oliva E, Skates SJ, Glyptis T, Fuller AF Jr, Goodman A, Seiden MV (2004) Expression of multidrug resistance-1 protein inversely correlates with paclitaxel response and survival in ovarian cancer patients: a study in serial samples. Gynecol Oncol 93:98–106CrossRefPubMed
36.
Materna V, Pleger J, Hoffmann U, Lage H (2004) RNA expression of MDR1/P-glycoprotein, DNA-topoisomerase I, trans and MRP2 in ovarian carcinoma patients: correlation with chemotherapeutic response. Gynecol Oncol 94:152–160CrossRefPubMed
37.
Yokoyama Y, Sato S, Fukushi Y, Sakamoto T, Futagami M, Saito Y (1999) Significance of multi-drug-resistant proteins in predicting chemotherapy response and prognosis in epithelial ovarian cancer. J Obstet Gynaecol Res 25:387–394CrossRefPubMed
38.
Ozalp SS, Yalcin OT, Tanir M, Kabukcuoglu S, Etiz E (2002) Multidrug resistance gene-1 (Pgp) expression in epithelial ovarian malignancies. Eur J Gynaecol Oncol 23:337–340PubMed
39.
Chen H, Hao JL, Wang L, Li Y (2009) Coexpression of invasive markers (uPA, CD44) and multiple drug resistance proteins (MDR1, MRP2) is correlated with epithelial ovarian cancer progression. Br J Cancer 101:432–440CrossRefPubMed
40.
Materna V, Liedert B, Thomale J, Lage H (2005) Protection of platinum-DNA adduct formation and reversal of cisplatin resistance by anti-MRP2 hammerhead ribozymes in human cancer cells. Int J Cancer 115:393–402CrossRefPubMed
41.
Ma JJ, Chen BL, Xin XY (2009) Inhibition of multi-drug resistance of ovarian carcinoma by small interfering RNA targeting to MRP2 gene. Arch Gynecol Obstet 279:149–157CrossRefPubMed
42.
Xu J, Xu HY, Zhang Q, Song F, Jiang JL, Yang XM, Mi L, Wen N, Tian R, Wang L, Yao H, Feng Q, Zhang Y, Xing JL, Zhu P, Chen ZN (2007) HAb18G/CD147 functions in invasion and metastasis of hepatocellular carcinoma. Mol Cancer Res 5:605–614CrossRefPubMed
43.
Dean NR, Newman JR, Helman EE, Zhang W, Safavy S, Weeks DM, Cunningham M, Snyder LA, Tang Y, Yan L, McNally LR, Buchsbaum DJ, Rosenthal EL (2009) Anti-EMMPRIN monoclonal antibody as a novel agent for therapy of head and neck cancer. Clin Cancer Res 15:4058–4065CrossRefPubMed
44.
Matsudaira H, Asakura T, Aoki K, Searashi Y, Matsuura T, Nakajima H, Tajiri H, Ohkawa K (2010) Target chemotherapy of anti-CD147 antibody-labeled liposome encapsulated GSH-DXR conjugate on CD147 highly expressed carcinoma cells. Int J Oncol 36:77–83PubMed
45.
Sonveaux P, Vegran F, Schroeder T, Wergin MC, Verrax J, Rabbani ZN, De Saedeleer CJ, Kennedy KM, Diepart C, Jordan BF, Kelley MJ, Gallez B, Wahl ML, Feron O, Dewhirst MW (2008) Targeting lactate-fueled respiration selectively kills hypoxic tumor cells in mice. J Clin Invest 118:3930–3942PubMed
Metadata
Title
Co-expression of CD147/EMMPRIN with monocarboxylate transporters and multiple drug resistance proteins is associated with epithelial ovarian cancer progression
Authors
Hongmin Chen
Li Wang
Julia Beretov
Jingli Hao
Weiwei Xiao
Yong Li
Publication date
01-12-2010
Publisher
Springer Netherlands
Published in
Clinical & Experimental Metastasis / Issue 8/2010
Print ISSN: 0262-0898
Electronic ISSN: 1573-7276
DOI
https://doi.org/10.1007/s10585-010-9345-9

Other articles of this Issue 8/2010

Clinical & Experimental Metastasis 8/2010 Go to the issue

Research Paper

Actin-sequestering protein, thymosin beta-4, is a novel hypoxia responsive regulator

Research Paper

Involvement of Hepatopoietin Cn in the development of human hepatocellular carcinoma

Research Paper

Serum follistatin in patients with prostate cancer metastatic to the bone

Research Paper

p-AKT overexpression in primary renal cell carcinomas and their metastases

Research Paper

Effects of dietary fat on spontaneous metastasis of Lewis lung carcinoma in mice

Research Paper

KISS1 over-expression suppresses metastasis of pancreatic adenocarcinoma in a xenograft mouse model
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits